ProBio

🔥📢 The first results from the @ProBioTrial have been published in @NatureMedicine 🚀🌟 ARPIs outperform taxanes in metastatic #ProstateCancer: an outcome-adaptive randomized platform trial 🌟 nature.com/articles/s4159… [1/10]

This research was made possible by the support of: @ALFmedicin , @Cancerfonden , Radiumhemmet Research Funds, @Prostatacancerforbundet, @Vetenskapsradet , Krebsliga beider Basel, & @KomOpTegenKanker THANK YOU! 🙏 [8/8] #CancerResearchMatters

What’s next? 🏥 @ProBioTrial will explore treatment de-escalation for low-ctDNA patients 🔬 Future trials should integrate ctDNA fraction 🩸🧬 as a stratification tool 👨‍⚕️ ctDNA may guide guide #PrecisionMedicine in all #ProstateCancer patients? [7/8]

🚨 New Study Alert! 🚨 What if a blood test 🩸 could infer prognosis in advanced prostate cancer? Our latest #ProBio trial study reveals the prognostic power of circulating tumor DNA (ctDNA) 🧬 in #mCRPC A thread 🧵👇 #CancerResearch #ProstateCancer [1/8]

AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j @ProBioTrial

AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the #ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j @ProBioTrial

AR pathway inhibitors vs taxanes in #mCRPC #ProBio trial. @BramDL @ugent joins @zklaassen_md @GACancerCenter to discuss the ProBio trial, a groundbreaking platform study in metastatic prostate cancer. Findings show that AR pathway inhibitors often outperform taxane-based chemo in mCRPC, with outcomes influenced by specific genomic markers. #WatchNow > bit.ly/3YXuh6j

Don’t forget the @ProBioTrial is an investigator-initiated trial! Crazy level of commitment of everyone involved.

Meet the @ProBioTrial consortium: healthcare professionals from 🇸🇪🇧🇪🇳🇴🇨🇭specialised in the treatment of men with metastatic #ProstateCancer They made the 🥈#ProBioTrial International Investigator’s Meeting a success 🙏 Presentations soon available on probiotrial.org

Final session of the day during the #ProBioTrial investigator meeting! 📢Tour de force from @okelidokeli 🏥🧪 the path towards getting the @ProBioTrial test into clinical routine diagnostics 🩸🧬

Next, the #ProBioTrial team tackles the new features protocol v6.0 will have: 1) Expansion of the #ProstateCancer patient population 2) A new treatment arm for ctDNA-undetectable mHSPC 3) Towards the removal of the SOC control arm in ProBio-mHSPC

Prof. Henrik Grönberg opening the 2nd #ProBioTrial International Investigators Meeting in Stockholm! 🌍 Healthcare professionals from 🇸🇪 🇧🇪 🇳🇴 🇨🇭 are coming together to push the boundaries of #ProstateCancer cancer research and treatment. Let’s make an impact! 💪